Russia’s Sputnik V vaccine shows impressive resistance to the new delta strain of the coronavirus, Gamaleya National Research Center of Epidemiology and Microbiology said.
The Russian drug against the COVID-19 has proven its effectiveness against the Delta strain of the SARS-CoV-2 coronavirus is 83 to 94 percent. The Gamaleya Center director, Alexander Guintsburg, said that the Russian vaccine that the vaccines from foreign drug companies Moderna and Pfizer have less than 50-percent effectiveness against this variant of the pathogen.
During a video conference, organized by the Russian Hebrew Congress, Guintsburg also said that data from the Ministries of Health show that revaccination after Sputnik V is possible with any drug, however, the manufacturer of another vaccine will be responsible for any side effects it causes.
‘The only thing I always add when answering this question is that the Gamaleya Center, the Russian state and Alexander Guintsburg are not responsible for the side effects caused by these vaccines, as compared to Sputnik V,’ Guintsburg pointed out.
The vaccine created by Gamaleya became the first one against the SARS-CoV-2 coronavirus officially accepted on the globe. The Sputnik V’s developers emphasize that by using two different vectors for two doses of the vaccine, a stronger and longer-lasting immune response is achieved. The vaccine has been registered in 70 countries so far, TASS reports.